PROGRAM OVERVIEW

Guided by national needs and based on the coordinated development of the Shenzhen Hong Kong Science and Technology Special Zone, we aim to cultivate high-level composite talents in "basic medicine+X" who are innovative and interdisciplinary.

Training objective: To benchmark the major strategic needs of "human health" and grasp the cutting-edge dynamics and development trends in the field of basic medical research; Integrating the characteristics of Shenzhen and Hong Kong, emphasizing interdisciplinary and practical applications, cultivating "basic medicine+X" composite medical professionals with solid basic medical theoretical knowledge and experimental skills, innovative spirit, good scientific and humanistic literacy, independent ability to engage in basic medical education, research and transformation, and international perspective.

CORE COURSES

Design and Writing of Research Projects, Advanced Experimental Techniques, Basic Medical Seminar Courses, Artificial Intelligence Medicine, Frontiers in Infection and Immunology, Frontiers in Medical Cell Biology, Advanced Physiology and Disease, Biochemistry and Molecular Biology, Molecular Pharmacology

CAREER PROSPECTS

Teaching and research positions in higher medical colleges, hospitals, research institutions, biotechnology companies.

Consultation

Email: [email protected]                

專業簡介

培養定位：以國家需求為導向，立足深港科技特區協同發展，培養“創新基石，學科交叉”的 “基礎醫學+X”高層次復合型人才。

培養目標：對標“健康中國”重大戰略需求，把握基礎醫學研究領域前沿動態和發展趨勢；融合深港特色，注重學科交叉和實踐應用，培養具有扎實的基礎醫學理論知識和實驗技能、創新精神、良好的科學人文素養、能夠獨立從事基礎醫學教育、研究與轉化，具有國際視野的“重基礎、精科研、能交叉、會轉化”的“基礎醫學+X”復合型醫學專業人才。

核心課程

科研項目設計與撰寫、先進實驗技術、基礎醫學seminar課程、人工智能醫學、感染與免疫學前沿、醫學細胞生物學前沿、高級生理學與疾病、生物化學與分子生物學、分子藥理學

就業前景

高等醫學院校、醫院、科研機構、生物技術公司等教學與研發崗位

咨詢方式

Email: [email protected]

英文名

Liu Baohua

聯系郵箱

Ppliew@szu.edu.cn

中文簡介

北京大學學士，香港大學博士，國家杰青、優青、青年特聘專家，廣東省優粵人才（A類），深圳市孔雀人才，深圳大學特聘教授，博士生導師，基礎醫學院院長，校學術委員會副主任（理工醫），國家生化工程技術研究中心（深圳）主任，深圳市系統衰老與主動健康重點實驗室主任。任亞洲衰老研究學會秘書長，中國老年醫學學會基礎與轉化醫學分會副會長，中國生物物理學會衰老生物學專業委員會副會長，中國老年學和老年醫學學會老年病學分會常務委員，中國細胞生物學會衰老細胞生物學分會常務委員。主持國家自然科學基金重大項目、香港研究資助局等科研基金，從事衰老機制與干預策略研究，在Nat Med, Cell Metab, Nat Metab, Sci Adv, Nat Commun, EMBO J, Elife 等國際高水平期刊發表學術論文，獲教育部自然科學二等獎[2022]、深圳市自然科學一等獎[2022]。

英文簡介

Bachelor's degree from Peking University, Ph.D. from the University of Hong Kong, The National Science Fund for Distinguished Young Scholars, Excellent Young Scientists Fund, Guangdong Province Excellent Talent (Category A), Shenzhen Peacock Talent, Distinguished Professor at Shenzhen University, Ph.D. Supervisor, Dean of the School of Basic Medicine, Deputy Director of the Academic Committee of the University(Medical Science and technology), Director of the National Biochemical Engineering Technology Research Center (Shenzhen), and Director of the Shenzhen Key Laboratory of System Aging and Active Health. He has led major projects funded by The National Natural Science Foundation of China and the Hong Kong Research Grants Council, conducting research on aging mechanisms and intervention strategies. He has published academic papers in high-level international journals such as Nat Med, Cell Metab, Nat Metab, Nat Aging, Sci Adv, Nat Commun, EMBO J, and Elife, and has received the Second Prize in Natural Science from the Ministry of Education [2022] and the First Prize in Natural Science from Shenzhen [2022].

英文名

Cai Yi

聯系郵箱

C[email protected]

中文簡介

蔡毅，長聘副教授，博士生導師，深圳大學生物安全三級實驗室副主任。長期從事結核感染發病機制研究，主要包括：1）結核發生發展與細胞異質性；2）細菌與宿主相互作用的機制；3）抗結核藥物篩選及其作用機制；4）結核感染宿主免疫保護機制。研究相關成果發表在Journal of Clinical Investigation，Journal of Experimental Medicine，PLOS Pathogens，mBio等雜志，發明專利11項，轉化1項，完成靶向宿主治療結核病藥物SASP臨床III期試驗。主持國家自然科學4項、深圳市學科布局項目1項、重點項目1項、深圳市醫科院一般項目等。相關成果獲廣東省科技進步獎二等獎，深圳市自然科學二等獎。

英文簡介

Dr. Yi Cai is currently an Associate Professor with Tenure in the Department of Pathogenic Biology, Shenzhen University Medical. His research interests lie in host-pathogen interactions and Tuberculosis (TB) disease progression. His primary research areas include: the relationship between cellular heterogeneity and tuberculosis development; the mechanisms of host-pathogen interactions in tuberculosis; screening and mechanisms of anti-tuberculosis drugs; host immune protection mechanisms against tuberculosis infection. His research findings have been published in journals such as Journal of Clinical Investigation, Journal of Experimental Medicine, PLOS Pathogens, and mBio. He holds 11 invention patents, with one successfully commercialized, and has completed a phase III clinical trial for the host-targeted tuberculosis drug SASP. He has led four projects funded by the National Natural Science Foundation of China and several grants from Shenzhen. His work has earned him the Second Prize of the Guangdong Provincial Science and Technology Progress Award and the Second Prize of the Shenzhen Natural Science Award.

英文名

Xue Liu

聯系郵箱

x[email protected]

中文簡介

劉雪, 深圳大學醫學部副教授，深圳市海外高層次人才，廣東省特支計劃青年拔尖人才獲得者。2021年8月入職深圳大學醫學部，組建人類病原性細菌研究團隊（http://xliugroup.com/）。近年發表SCI論文20余篇，其中第一作者（含共同一作）論文10篇，包括Cell Host & Microbe, Molecular Cell, Nature Protocols, Molecular Systems Biology (封面文章）等國際知名高水平期刊。首次鑒定了LafB可為廣譜的鏈球菌菌的疫苗靶點，并獲國際專利1項。

“克菌治病”課題組目前研究方向包括以下三個方面：

1） 重要人類病原細菌的致病機理。

2） 腸道非模式細菌的高效遺傳篩選平臺開發。

3)  采用時空組學探究細菌感染關鍵病灶的發病機制。

英文簡介

Liu Xue is an associate professor at the Medical School of Shenzhen University, a high-level overseas talent in Shenzhen, and a recipient of the Guangdong Province Special Support Program for Young Talents. In August 2021, she joined the Medical School of Shenzhen University and established the Human Pathogenic Bacteria Research Team (http://xliugroup.com/). In recent years, she has published more than 20 SCI papers, including 9 as the first author or co-first author, in internationally renowned high-level journals such as Cell Host & Microbe, Molecular Cell, Nature Protocols, and Molecular Systems Biology (cover article). She identified LafB as a target for pneumococcal vaccine develop with wide-range protection against strains with different serotypes.

Our "Fighting Bacterial Diseases" research group is currently focused on three main areas:

1) The pathogenic mechanisms of important bacterial human pathogens.

2) The development of efficient genetic screening platforms for non-model bacteria in the gut.

3) Using spatial and temporal omics to explore the pathogenesis of key lesions in bacterial infections.

英文名

Huiqiang Lou

聯系郵箱

l[email protected]

中文簡介

 樓慧強，博士，深圳大學醫學部特聘教授。1997年本科畢業于北京大學生命科學學院，2004年博士畢業于中國科學院微生物研究所。2004-2009年在加州理工學院先后從事博士后、CIRM fellow 工作，2009-2020年中國農業大學生物學院教授、博導，歷任微生物學與免疫學系系主任、科研副院長、農業生物技術國家重點實驗室副主任。擔任中國微生物學會理事、《微生物學報》、《mLife》、《Engineering Microbiology》編委。

主要從事糖代謝與DNA復制研究。主持國家自然科學基金重點項目1項、面上項目4項、參與國家“重點研發”重大專項子課題1項。近5年以通訊作者在Gen & Dev、EMBO Rep、CMLS、Cell Rep、PLoS Genet等雜志發表論文30余篇；獲得國家發明專利2項，申請PCT專利2項。

英文簡介

The Lou Group is devoted to uncover the potential crosstalk between metabolic dysregulation and genome instability, the two major resources which are considered to underlie cancer initiation. We apply multidisciplinary approaches such as genetics, biochemistry, cell biology, quantitative biology and synthetic biology to investigate DNA replication, co-replication events and whether/how sugar metabolism affects DNA replication/genome integrity. Our recent high-impact publications include Genes & Dev, EMBOJ, Cell Rep, EMBO Rep, CMLS, PLoS Genet.  

英文名

Sisi Li

聯系郵箱

[email protected]

中文簡介

2013年獲復旦大學博士學位，隨后加入紐約紀念斯隆凱特琳癌癥中心（MSKCC）從事博士后研究。2016-2021年任南方科技大學生物系研究副教授，2021年加入深圳大學卡爾森國際腫瘤中心任特聘教授。 國家級青年人才，深圳市杰出青年人才。

李思思博士近年來專注RNA轉錄后調控的機制研究，通過多種生物學研究手段，建立從RNA的化學結構，到RNA與相關蛋白質的調控機制與生理功能，最后到RNA藥物開發的聯合體系。近五年來以第一或通訊（含共同）作者身份在Science、 Nat Commun和 PNAS等學術期刊上發表學術論文十余篇，部分研究成果獲同期專評，以及學術媒體Faculty Opinion的推薦，并擔任多個知名期刊的審稿人。

英文簡介

Dr. Li Sisi obtained her Ph.D. degree from Fudan University in 2013, and joined the Memorial Sloan Kettering Cancer Center in New York for postdoctoral research. From 2016 to 2021, she was an Associate Professor at the Department of Biology at Southern University of Science and Technology, and in 2021, she joined the Carlson International Cancer Center at Shenzhen University as professor. She was awarded the National Science Foundation for Outstanding Young Scholars and Outstanding Young Talents of Shenzhen.

In recent years, Dr. Li has focused on the mechanisms of RNA post-transcriptional regulation. Using various biological research methods, she has established a joint system from the chemical structure of RNA to the regulation mechanism and physiological function of RNA with relevant proteins, and finally to RNA drug development. In the past five years, she has published over ten academic papers as the first or corresponding author in high-profile journals such as Science, Nature Communications, and PNAS. Some of her research achievements have received specialized reviews and recommendations from academic media such as Faculty Opinion, and she has also served as a reviewer for several well-known journals.

英文名

Yin Peng

聯系郵箱

y[email protected]

中文簡介

2010年畢業于Loyola University Chicago獲生物醫學博士學位。現任深圳大學醫學部病理學系副教授。主要研究方向是胃腸道腫瘤中的非編碼RNA作用機制及其相關信號通路，發表SCI一作和通訊作者論文20篇，包括 Oncogene，Molecular Cancer，Cancer Letters等。主持國家自然科學基金2項、廣東省自然科學基金2項及廣東省醫學科學基金，深圳市基礎研究，深圳高層次人才基金，深圳大學啟動基金等多個項目，總經費超過500萬。美國腫瘤學會AACR會員。深圳市孔雀C類人才。

英文簡介

Dr. Yin Peng received the PhD degree in Molecular and Cellular Biochemistry from Loyola University Chicago in 2010. She is currently an associate professor in Department of Pathology at Shenzhen University, China. Her long-standing research interests lie in elucidating the molecular mechanisms of cell signaling transduction pathway underlying tumorigenesis. Her lab is actively exploring how oncogenic circRNAs regulate critical signaling transduction pathways, such as the Wnt/β -catenin pathway and NF-κB signaling pathway to promote cell survival, proliferation and migration in cancer cells. She has published over 20 first author/corresponding author papers in professional, peer-reviewed journals including Oncogene, Molecular Cancer, Cancer Letters. She is an AACR member and Shenzhen Peacock Talent C.

英文名

Yong-Xian Cheng

聯系郵箱

[email protected]

中文簡介

程永現，深圳大學特聘教授，藥學院院長，長期從事中藥科學原理研究與新藥轉化工作，主要是在中醫藥理論和仿生學啟發下，運用“衷中參西”的方法圍繞重大疾病和“未病”開展中藥有效成分的發現與作用機制、中藥配伍原理指導下的結構優化以及中藥有效成分挖掘的方法學研究。迄今已在Organic letters, Natural Product Reports, Acta Pharmaceutica Sinica B, British Journal of Pharmacology, Medicinal Research Reviews等國內外核心期刊發表學術論文150余篇。近年來主持或完成國家杰出青年科學基金、國家自然科學基金委員會-云南省聯合基金重點項目等多項基金。其帶領的團隊以“回歸臨床”為終極目標，借鑒中醫象思維模式，注重方法和策略開發，試圖采用化學生物學、醫工結合等手段，以中藥小分子化合物或中醫治療方法為工具探索五臟之間的生克制化規律、天然分子的生化機制等，借此發現新的病理機制或有效藥物，也闡釋中醫藥療效的科學內涵。目前研究方向主要有：調控重大疾病及未病的中醫藥智慧設計、特色中藥藥效物質挖掘及天然可及性研究；具有成藥前景中藥成分的有機全合成及工藝優化研究；中藥有效或毒性成分的分子設計、結構修飾與優化；中藥有效成分的作用機制及器官間生克制化的規律研究；中藥有效成分為探針的疾病新靶標發現與確證研究；中藥有效成分的生物合成途徑解析及合成生物學研究。

英文簡介

Yongxian Cheng is a distinguished professor at Shenzhen University and the Dean of the School of Pharmacy. He has long been engaged in research on the scientific principles of traditional Chinese medicine (TCM) and the translation of new drugs. His work primarily focuses on the discovery and mechanism of action of effective components in TCM, structural optimization guided by TCM compatibility principles, and methodological research on the extraction of effective components, all inspired by TCM theory and biomimicry. To date, he has published over 150 academic papers in core journals such as Organic letters, Natural Product Reports, Acta Pharmaceutica Sinica B, British Journal of Pharmacology, Medicinal Research Reviews.

In recent years, he has led or completed several projects funded by the National Science Fund for Distinguished Young Scholars and key projects under the National Natural Science Foundation of China and Yunnan Province Joint Fund. His team aims to "return to clinical practice" as the ultimate goal, utilizing TCM symbolic thinking and emphasizing method and strategy development. They attempt to use chemical biology and the integration of medicine and engineering to explore the interactions between the five organs and the biochemical mechanisms of natural molecules, employing TCM small molecules or therapeutic methods as tools to discover new pathological mechanisms or effective drugs, and to elucidate the scientific connotations of TCM efficacy.

Current research directions include: intelligent design of TCM for the regulation of major diseases and preventive medicine; exploration of effective substances in characteristic TCM and studies on natural accessibility; organic total synthesis and process optimization of TCM components with drug potential; molecular design, structural modification, and optimization of effective or toxic components in TCM; studies on the mechanisms of action of effective components and the rules of interactions between organs; discovery and verification of new disease targets using effective components in TCM as probes; and analysis of biosynthetic pathways of effective components and research in synthetic biology.

英文名

Liu Qi

聯系郵箱

[email protected]

中文簡介

德國海德堡大學獲得放射治療學博士博士，深圳大學醫學部卡爾森國際腫瘤中心副教授。先后在美國哈佛大學醫學院作為博士后研究員、加州大學舊金山分校擔任項目科學家開展放射腫瘤學研究。劉琦博士長期從事放射醫學與癌癥精準醫療的臨床前研究，作為課題負責人帶領團隊研究了癌癥的DNA損傷反應、腫瘤放療免疫學影響、藥物靶點相關機制、硼中子俘獲療法及放射性核素藥物等課題。研究成果包括建立了世界首個放射增敏靶向藥物篩選平臺，攻克了人乳頭瘤病毒影響腫瘤放射敏感性機制的難題，揭示了質子射線造成的DNA損傷特點及其修復機制等。現已發表SCI論文50余篇，多項重要研究成果以第一作者發表在Science Translational Medicine、Clinical Cancer Research、Oncogene等國際著名學術期刊上；擔任多個SCI學術期刊的編委及審稿專家；是國際放射研究學會、美國癌癥研究學會、中華放射腫瘤專業委員會、中國核學會放射性藥物分會等學術組織成員。

英文簡介

Dr. Liu Qi received his Ph.D. in Radiation Therapy and Oncology from Heidelberg University in Germany, currently serve as an associate professor at the International Cancer Center, School of Medicine, Shenzhen University. He was a postdoctoral research fellow at Harvard Medical School and an associate scientist at the University of California, San Francisco. Dr. Liu is an enthusiastic researcher in precision cancer medicine. In the past decade, he has studied mechanisms of DNA damage response, molecular targeted radiation therapy, boron neutron capture therapy, and radiopharmaceuticals for cancer treatment. His pioneer work has given rise to the world's first high-throughput screening platform for identifying molecular targeted drugs with radiosensitizing properties, discovery of DNA damage features caused by proton beams and their repair mechanisms, revelation about HPV induced radiation response in head and neck cancer, etc. Dr. Liu has published over 50 academic articles in the renowned journals such as Science Translational Medicine, Clinical Cancer Research, etc. Dr. Liu serves as an editorial board member and reviewer for a number of SCI journals, and members in Radiation Research Society, American Association for Cancer Research, Chinese Society of Radiation Oncology, etc.

英文名

Bin Peng

聯系郵箱

[email protected]

中文簡介

彭斌，副教授，博士生導師，特聘研究員，深圳市高層次人才。長期致力于基因組不穩定性與人類疾病（如腫瘤、先天性小頭畸形）方面的研究，側重于翻譯后修飾調控DNA損傷/DNA復制脅迫應答的分子機制，并聚焦靶向基因組穩定性的抗癌先導物篩選及分子機制闡明。以一作或通訊作者在國際主流雜志PNAS、NAR、eLife、iScience、Cell & Bioscience和EJMC等發表SCI 論文20余篇。主持國家重點研發計劃子課題，國家自然科學基金面上項目、青年項目，廣東省自然科學基金青年提升、面上項目，深圳市科技計劃基礎研究項目等7個縱向科研基金。參與國家自然科學基金重大項目、重點項目及國際合作等5項。

英文簡介

Dr. Peng Bin, an associate professor with tenure in the Department of Cell Biology, Shenzhen University Medical School. He focuses on the molecular mechanisms of the DNA damage response and human diseases (such as cancer, primary microcephaly), especially addressing how the posttranslational modifications (PTMs) regulate the DNA damage response. He has published more than 20 papers in PNAS, NAR, eLife, iScience, Cell & Bioscience and EJMC. (1) The molecular mechanism of DNA damage response and tumorigenesis. (2) Elucidation of the pathogenic mechanistic link between genome instability and primary microcephaly. (3) Development of anti-cancer lead compounds targeting genome stability, screening and characterizing anti-cancer lead compounds such as chalcone and quinazoline derivatives, and revealing their anti-cancer mechanism.

英文名

SHU, Xingsheng

聯系郵箱

[email protected]

中文簡介

舒興盛，博士，副教授，博士生導師，深圳大學“荔園優青”，深圳市海外高層次人才，本科畢業于北京大學生命科學學院，博士畢業于香港中文大學醫學院，現任深圳大學醫學部基礎醫學院副教授、特聘研究員。舒興盛副教授長期致力于腫瘤轉錄和表觀遺傳調控異常的機制及相關的轉化治療研究，以通訊或第一作者在PNAS，Cancer Research，Oncogene和Journal of Pathology等國際權威學術期刊發表論文三十余篇，被引用1500余次，H-index為21，以第一發明人獲得兩項中國發明專利授權，主持包括國自然面上項目在內的多項國家和省市級項目，擔任國際表觀遺傳協會理事。指導研究生獲深圳大學“百篇優秀碩士學位論文”和深圳大學優秀畢業生等榮譽。更多研究情況請參看鏈接：https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/。

英文簡介

Dr. Xing-sheng Shu received his B.S. degree from the School of Life Sciences, Peking University and his Ph.D. degree from the Department of Clinical Oncology, The Chinese University of Hong Kong. He is currently an Associate Professor at the School of Medicine, Shenzhen University. Dr. Shu has been working on abnormal epigenetic and transcriptional regulation in cancer and related translational research for cancer therapy. He has published more than 30 SCI papers with more than 1500 citations and an H-index of 20, including more than 10 papers in PNAS, Oncogene, Cancer Resarch, Journal of Pathology and other high impact journals in recent 5 years as corresponding or first author. He also holds two invention patents, and completed many national and provincial research projects. Graduate students supervised by Dr. Shu were awarded by “One Hundred Outstanding Master's Degree Theses of Shenzhen University” and “Outstanding Graduate of Shenzhen University”. For more information about his research, please refer to the link: https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/.

英文名

Lei Wang

聯系郵箱

[email protected]

中文簡介

香港科技大學本科與碩士學位，美國加州大學河濱分校博士學位，美國希望之城(City of Hope)國家醫學中心博士后。研究方向長期聚焦腫瘤免疫學, 與臨床醫生緊密合作，運用單細胞多組學、空間多組學和高參數流式細胞術等技術，結合生物信息學，探究腫瘤發生發展對患者全身性免疫系統的影響作用，揭示免疫療效機理機制，并尋找免疫治療標志物。近年來以第一作者在Nature Immunology等國際刊物共發表學術論文10余篇，現主持國自然重大研究計劃培育項目等科研項目。

英文簡介

The focus of my research is on exploring how immunotherapy impacts the dynamic of immune responses in patients with solid tumors, with the goal of understanding the immunoregulatory mechanisms of host systemic immunity and developing novel prognostic/predictive biomarkers. We utilize state-of-the-art technologies – such as single-cell multiomics, quantitative spatial image analysis, high-parameter flow cytometry and advance bioinformatics – to dissect the complex interplay between immune cells and cancer cells within tumor microenvironment and host immune macroenvironment including tumor-draining lymph nodes and peripheral blood.

英文名

XU, Xingzhi

聯系郵箱

[email protected]

中文簡介

深圳大學特聘教授、醫學部執行主任，國際先進材料協會（IAAM）會士，《Genome Instability & Disease》常務主編、中國細胞生物學學會細胞信號轉導分會副會長（2015-2023）。長期致力于DNA損傷應答、DNA復制及復制應激、基因組穩定性維持的研究，并開發靶向基因組穩定性的抗癌先導化合物。在國際主流雜志發表SCI論文100余篇；主編《腫瘤生物學導論》（科學出版社，2014）。2011年創建DNA損傷應答北京市重點實驗室并任主任（2011-2017）；2010年創辦并連續主辦DNA損傷應答與人類疾病國際研討會（isDDRHD）年會系列并成為有國際影響力的品牌會議，是中國DNA修復領域的核心召集人。

英文簡介

Distinguished Professor of Shenzhen University,Executive Dean of School of Medicine, Fellow of the International Association for Advanced Materials (IAAM), Deputy Editor-in-chief of Genome Instability & Disease, Vice President of Chinese Society for Cell Signal Transduction, CSCB (2015-2023). He has long been devoted to the research of DNA damage response, DNA replication and replication stress response, and maintenance of genome stability, and has developed anticancer lead compounds targeting genome homeostasis. He has published more than 100 SCI papers in international mainstream journals; edited "Principles of Cancer Biology" (Science Press, 2014). In 2011, he founded the Beijing Key Laboratory of DNA Damage Response and served as the director (2011-2017); in 2010, he founded and successively hosted the annual conference series of the international symposium on DNA Damage Response and Human Diseases (isDDRHD), which has become an internationally influential brand conference. Therefore, he becomes the core convener in the field of DNA repair in China.

英文名

YING YING

聯系郵箱

[email protected]

中文簡介

應穎，教授，博士生導師，深圳市海外高層次B類人才，醫學部基礎醫學院副院長兼生理學系主任。長期從事表觀遺傳變異所致的轉錄調控異常參與代謝性、神經退行性疾病及腫瘤的發生發展的分子機制及干預研究。主持國家自然科學基金4項及省、市級項目多項。以第一或通訊作者（含共同）在Molecular Neurodegeneration, PNAS, Cancer Research, Oncogene, Journal of Pathology等國際著名期刊上發表論文30余篇。

英文簡介

Prof. Ying Ying (MD, PhD) is Vice Dean of the Department of Physiology at Shenzhen University Health Science Center. Her research focuses on epigenetic dysregulation in contribution to the pathogenesis of metabolic and neurodegenerative diseases as well as colorectal cancer. She has presided over the completion of a number of research projects including the National Natural Science Foundation of China. As the corresponding author or first author, she has published over 30 research articles in top journals (i.e.,Molecular Neurodegeneration, PNAS, Cancer Research, Oncogene, Journal of Pathology, etc.).

英文名

Jingzhu Zhang

聯系郵箱

[email protected]

中文簡介

張景筑，博士，深圳大學醫學部百人計劃助理教授，特聘研究員，獨立PI，博士生導師。本科畢業于美國威斯康星大學麥迪遜分校，博士畢業于圣路易斯華盛頓大學，后于德克薩斯大學西南醫學中心的Sean Morrison教授（美國科學院與醫學院院士，HHMI研究員）課題組從事博士后研究，并于2024年3月入職深圳大學。張景筑博士長期研究骨骼與骨髓微環境，累計發表SCI論文10篇，其中以第一作者發表論文4篇，包括PNAS（兩篇）、Journal of Clinical Investigation與Journal of Bone and Mineral Research等國際高水平期刊。

研究方向：骨髓微環境、骨骼干細胞、骨再生、骨衰老、骨損傷修復

英文簡介

Jingzhu Zhang, Ph.D., is a Hundred-Talents assistant professor at the Medical School of Shenzhen University, principal investigator and supervisor of Ph.D./master students. He received his B.S. degree from the University of Wisconsin-Medicine in the U.S.A., and Ph.D. degree from the Washington University in St. Louis, and completed his postdoctoral fellowship in the University of Texas Southwestern Medical Center supervised by Dr. Sean Morrison (member of National Academy of Science and National Academy of Medicine of the U.S.A., and investigator of Howard Hughes Medical Institute). In March, 2024, Dr. Zhang joined Shenzhen University. Dr. Zhang has been focusing on the research of bone and bone marrow microenvironment, and has published 10 SCI papers. As first-author, he published in internationally renowned high-level journals including PNAS (2 papers), Journal of Clinical Investigation and Journal of Bone and Mineral Research.

Research interest: Bone marrow microenvironment, skeletal stem cell, bone regeneration, bone aging, bone repair

英文名

Suping Zhang

聯系郵箱

[email protected]

中文簡介

2007年獲清華大學博士學位，隨后加入加州大學圣地亞哥分校從事博士后科學研究，2012年留校任教。2015年被深圳大學聘為副教授;2023年晉升為教授，博士生導師。張博士長期致力于腫瘤生物學及免疫靶向治療新藥的研究，利用細胞生物學、生物化學、分子生物學、免疫學、生物信息學等多學科分析方法,研究腫瘤發生、發展、轉移及復發的機制及尋找新的治療靶標，據此開發靶向消除腫瘤細胞或改變其微環境的免疫治療新藥有望治愈癌癥。到目前為止，張博士主要開發的進入臨床試驗階段的用于免疫治療的一類新藥有兩個;發表高水平學術論文27篇，其中第一作者及通訊作者論文16篇(含3篇PNAS)，引用次數超過2000。擁有國內外發明專利9項，其中一項已經商業化。承擔國家重點研發計劃、國家自然科學基金面上項目、深圳市海外創新孔雀團隊等項目共11項。2011年獲第53屆美國血液學年會摘要成就獎。

英文簡介

Dr. Zhang obtained her PhD degree from Tsinghua University in 2007, and then joined the University of California, San Diego for postdoctoral scientific research, and stayed in the university as a faculty member in 2012. She was appointed as Associate Professor by Shenzhen University in 2015; and was promoted to Professor in 2023. Dr Zhang’s research interests lie in: Using multidisciplinary approach of molecule cell biology, cell biology, biochemistry, immunology and bioinformatics to investigate the molecular mechanism underlying tumor initiation, metastasis and relapse, and develop novel small compounds and immunological therapeutics for patients with cancer. So far, Dr. Zhang has developed two novel anti-cancer drugs which are under clinical investigation currently.  She had co-authored 27 publications which include 3 PNAS and one publication on Oncogene as first or corresponding authors. She had 9 patents and one of them already was commercialized. She has been funded by National Key R&D plan, National Natural Science Foundation of China (NSFC), Shenzhen Peacock Innovation Team Grant and so on. She had been awarded “Excellent Abstract Achievement” by American Society of Hematology (ASH) at 2011.

英文名

SHUNICHI TAKEDA

聯系郵箱

sta[email protected]

中文簡介

武田教授的實驗室主要研究抗癌藥物的分子機制。我們的研究目標是提供一種可預測不同抗癌療法對不同癌癥患者治療療效的情況，并為每個患者提供最佳的治療。每個患者的癌癥特征都有很大的不同，例如，每個癌基因的活性和抗癌治療的療效在每個乳腺癌患者之間都有很大的不同。在不久的將來，有可能可以確定每個惡性腫瘤病人中許多基因的活性狀態。抗癌藥物會殺死循環中的正常細胞，產生非常嚴重的副作用。因此，在實際治療前預測抗癌藥物的療效和副作用的發生是非常重要的。武田教授的實驗室一直致力于干擾人類癌細胞中的基因研究，并檢測每個基因的活性對抗癌藥物療效的影響。本研究將有助于通過分析惡性腫瘤中基因的活性狀態來預測不同療法的療效。這項研究也讓學生系統地學習基因研究的方法，包括基因破壞和基因破壞細胞的許多表型分析，與大家分享更多基因的突變細胞進行科學研究。

英文簡介

Prof. Takeda’s laboratory has investigated molecular mechanisms underlying anti-cancer drugs. The goal of our study is to develop the method of predicting the efficacy of various anti-cancer therapies on individual cancer patients and to offer the best therapy to each patient. The character of cancers arising in each patient significantly vary, for example, each oncogene’s activity and the efficacy of anti-cancer therapies are very different from one breast cancer patient to another. It is possible in the near future to determine the activity status of many genes in each patient’s malignant tumor. Anti-cancer drugs kill actively cycling normal cells causing very severe side effects. Thus, it is very important to anticipate the efficacy of anti-cancer drugs and the occurrence of side effects before actual treatments. Prof. Takeda’s laboratory has been disrupting genes in human cancer cells and examining the effect of each gene’s activity on the efficacy of anti-cancer drugs. This study will contribute to the prediction of different therapies’ efficacy by analyzing the activity status of genes in malignant tumors. This study also allows students to systematically learn methods of the genetic study, including gene disruption and many phenotypic analyses of gene-disrupted cells, sharing mutant cells of many genes with colleagues.

英文名

Gang Fan

聯系郵箱

gang[email protected]

中文簡介

醫學博士，醫師，副研究員。畢業于中國醫科大學獲學士學位，中南大學獲碩士學位，2016年國家公派德國洪堡大學Charite醫學院，2020年獲博士學位。發表學術論文三十余篇。主持或參與學術課題多項，包括主持國家自然科學基金面上項目一項，國家自然科學基金青年項目一項，深圳市醫學研究專項資金項目（SMART)一項，廣東省自然科學基金項目二項，廣東省醫學科研基金項目一項，深圳市自然科學基金項目二項，深圳南山區衛生健康系統科技重大項目一項；參與德國科學基金會（DFG）一項，德國學術交流中心項目一項。獲得2021年德DAAD獎學金、第十四屆教育部春暉杯優勝獎、第十五屆湖南省醫學科技三等獎。研究方向: 血管衰老、泌尿系疾病。

英文簡介

Dr. Gang Fan is a medical doctor, physician, and associate researcher with a diverse educational and research background. He obtained his Bachelor's degree from China Medical University, a Master's degree from Central South University, and completed his doctoral studies under a national scholarship at Humboldt University's Charite Medical School in Germany in 2020. With a strong publication record of over thirty academic papers, he has demonstrated a commitment to advancing knowledge in the field of medicine. Dr. Gang has led or participated in numerous research projects, including serving as the principal investigator for two National Natural Science Foundation of China , a Shenzhen Medical Research Fund project (SMART), two Guangdong Provincial Natural Science Foundation projects, a Guangdong Provincial Medical Research Fund project, two Shenzhen Natural Science Foundation projects. He has also been involved in projects funded by the German Research Foundation (DFG) and the German Academic Exchange Service. In recognition of his contributions to academia, Dr. Gang has been awarded the 2021 DAAD Scholarship, the 14th Ministry of Education Spring Cup Outstanding Award, and the 15th Hunan Province Medical Science and Technology Third Prize. His research interests center around vascular aging and urological diseases, reflecting her dedication to exploring new insights in these areas of medical science.

英文名

Li-Yun Gong

聯系郵箱

[email protected]

中文簡介

鞏麗云，女，醫學博士，教授，博士研究生導師，獨立PI。深圳市生物化學與分子生物學會理事，廣東省生物化學與分子生物學學會常委，廣東省醫學教育協會生物化學與分子生物學專業委員會委員，美國國立衛生研究院（NIH）美國國立癌癥研究所（NCI）Guest Researcher。主持多項國家自然科學基金、廣東省自然科學基金項目和深圳市醫科院等研究項目，在Clinical Cancer Research，Oncogene，Nucleic Acids Research ，Journal of Pathology，Cell Death&Disease，Journal of Experimental & Clinical Cancer Research等期刊發表研究論文多篇，授權國家發明專利1項。目前研究方向：非小細胞肺癌（NSCLC）EGFR-TKIs靶向藥物耐藥的機制研究；LincRNA調控肺癌轉移的分子機制研究；絲-精氨酸蛋白激酶（SRPK1）調控糖代謝和核苷酸代謝促進耐藥的機制研究。

英文簡介

Li-Yun Gong, Doctor of Medicine, Doctoral Supervisor, member of the Biochemistry and Molecular Biology Professional Committee of the Guangdong Medical Education Association, and Guest Researcher of the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in the United States.

Led and participated in multiple research projects such as the National Natural Science Foundation of China, Guangdong Provincial Natural Science Foundation, and Shenzhen Free Exploration, and published multiple research papers in authoritative TOP journals such as Clinical Cancer Research, Journal of Pathology, Cell Death&Disease, and Oncogene.

Currently engaged in research on the mechanism of resistance of serine arginine protein kinase 1 (SRPK1) to the targeted drug EGFR-TKI in non-small cell lung cancer.

英文名

Yue HAO

聯系郵箱

[email protected]

中文簡介

郝悅，女，博士。深圳大學醫學部藥學院副教授、深圳大學博士生導師，新銳碩士生導師。美國 The Scripps Research Institute博士后、高級研究員。主要研究方向：神經病理性疼痛、神經損傷修復，及神經藥理學。主持國家自然科學基金面上項目2項、國家自然科學基金青年項目1項、深圳市基礎研究面上項目和企業橫向課題多項。在Biol Psychiatry，Acta Pharm Sin B，Theranostics等TOP學術期刊發表研究論文40余篇。美國神經學會會員，中國藥理學會會員。深圳市孔雀計劃人才、深圳市高層次人才、深圳市南山區領航人才。

英文簡介

Yue Hao, PhD. Associate Professor，PhD Supervisor in School of Pharmacy, School of Medicine, Shenzhen University. Postdoctoral fellow and senior research associate at The Scripps Research Institute, USA. Main research directions: neuropathic pain, nerve damage repair and neuropharmacology. Principle investigator of 2 general program and 1 youth project of National Natural Science Foundation of China, 3 general project of Science Foundation of Shenzhen and several corporate research projects. Published more than 40 research papers in top academic journals, such as Biol Psychiatry, Acta Pharm Sin B, Theranostics, etc. Member of Society for Neuroscience, member of the Chinese Pharmacological Society. Shenzhen Peacock Plan Talent, Shenzhen High-level Talent, Shenzhen Nanshan District Pilot Talent.

英文名

XIN-HAI PEI

聯系郵箱

p[email protected]

中文簡介

特聘教授，解剖組胚系主任, 動物中心主任，曾任美國北卡大學助理教授，邁阿密大學終身軌副教授。主要采用基因工程小鼠研究細胞增殖，分化和DNA損傷修復在疾病中的作用與機制。制備和鑒定了51種不同品系基因敲除和轉基因小鼠。首次證明Cu19和p19為抑癌基因，BRCA1-GATA3軸抑制腫瘤，BRCA1促進耳蝸毛細胞DNA損傷修復。曾主持13項270余萬美元美國聯邦和大學科研項目。兩次美國CDMRP-乳腺癌研究獎獲得者。2018年底起受聘深圳大學特聘教授，籌建，管理深圳大學動物中心。現主持5項國家及省市科研項目。近四年以通訊作者發表中科院一區或自然指數期刊論文9篇。

英文簡介

Dr. Pei is interested in using mouse genetic approaches to investigating the molecular and cellular basis of disease development. Dr. Pei generated and characterized 51 different mouse mutants for various cell cycle inhibitors and tumor suppressors, and demonstrated their functions in the control of stem cells and tumorigenesis of multiple tissues. Dr. Pei discovered that p18^INK4c is a downstream target of GATA3 and restrains mammary luminal progenitor proliferation and tumorigenesis (Pei XH, Cancer Cell, 2009).  As a tenure track assistant and associate professor at the University of Miami, Dr. Pei published 17 research papers. He discovered that deletion of Brca1 causes luminal-to-basal mammary tumor transformation (Bai F, Oncogene, 2013), and promotes EMT during tumor development (Bai F, Cancer Res., 2014). Since Oct 2018, Dr. Pei has been moving to China and working as a full professor at the Shenzhen University Medical School. In addition to the abovementioned areas, he is also very interested in 1) how DNA damage contributes to tumor cell de-differentiation; 2) how cell cycle inhibitors and transcription factors control cochlea hair cells in hearing loss and tubular cells in kidney disease. Recently, he discovered that GATA3 functions downstream of BRCA1 to suppress EMT in cancers (Bai F, Theranostics, 2021; 2022; Bai F, Cell Death Dis., 2022; Liu X, Cell Cell Death Dis., 2023), and BRCA1 promotes repair of DNA damage in cochlear hair cells and prevents hearing loss (Jiang W, J Neurosci, 2024).

英文名

Ren Jiangdong

聯系郵箱

[email protected]

中文簡介

男，44歲，深圳南山醫院骨關節科主任，主任醫師，博士。擅長人工髖膝關節置換，假體松動、感染一期翻修。人工智能機器人輔助下人工關節置換；髖部骨折（股骨頸骨折以及股骨粗隆間骨折）。骨關節炎發病機制研究，假體周圍感染的診斷與治療機制研究。

英文簡介

Male, 44 years old, Director of the Department of Arthroplasty at Shenzhen Nanshan Hospital, Chief Physician, PhD. Specializes in total hip and knee replacements, revision surgery for prosthesis loosening and infection, and  joint replacement assisted by  robotic assisted technique. Expertise also includes the management of hip fractures (including neck and intertrochanteric fractures), as well as research into the pathogenesis of osteoarthritis and the diagnostic and therapeutic mechanisms of periprosthetic joint infections.

英文名

Qi Sun

聯系郵箱

[email protected]

中文簡介

孫琦，深圳大學，副教授，日本京都大學博士畢業，深圳市海外高層次人才，深圳市南山區領航人才。在Angew Chem Int Ed Engl., British journal of pharmacology, Cell Commun Signal., 等國際國內著名刊物中發表學術論文30余篇；主持國家面上項目1項，國家青年科學基金項目1項、廣東省自然科學基金4項，深圳市高層次人才啟動項目1項，深圳市科技計劃項目1項。長期從事腫瘤信號通路轉導和藥理學作用機制研究。首次發現含硫金屬銥配合物PbtIrSS通過靶向Wnt/β-catenin通路中的共受體蛋白LRP6，與傳統的化療藥物順鉑相比，更有效的抑制乳腺癌的生長轉移和乳腺癌干細胞。其研究揭示了金屬類抗腫瘤藥物的潛在新靶點，并為新穎金屬類抗腫瘤藥物的研發開辟了新的思路。

英文簡介

Qi Sun

Associate professor

Fields of research

Tumor signal transduction pathway, Molecular-Targeting Cancer therapy, Antitumor drug development

英文名

Liang Ye

聯系郵箱

[email protected]

中文簡介

葉亮，深圳大學醫學部副教授，特聘研究員，卡爾森國際腫瘤中心獨立PI。“珠江人才計劃”青年拔尖人才、深圳市海外高層“孔雀計劃”B類人才。以第一作者或通訊作者身份在Nat. Immunol、Nat. Rev. Immunol、J. Virol.、J. Immunol.、Theranostics等期刊發表論文，成果被Nature Immunology、eLife 期刊發表重點專題點評。課題組長期從事病毒感染與宿主免疫機制研究。利用多種基因缺陷小鼠和條件性敲除小鼠構建病毒感染動物模型，重點探究干擾素系統抗病毒感染的免疫調控機理，從表觀遺傳修飾角度解析病毒逃逸宿主免疫和入侵宿主的作用機理，開發新型病毒疫苗與納米中和抗體，為遏制病毒感染性疾病的診斷、預防和治療提供新策略。

英文簡介

Liang Ye is an associate professor, distinguished researcher, and independent PI of the Shenzhen University Health Science Center. "Pearl River Talent Program" young top talents, Shenzhen overseas high-level "Peacock Program" category B talents. Our findings have been published in Nat. Immunol, Nat. Rev. Immunol, J. Virol., J. Immunol., Theranostics, and other journals and have been widely cited by Nature Immunology and eLife journals. Our group was interested in the immunoregulatory mechanism of host defense against viral infection. We developed a variety of gene-deficient mice and conditional knockout mice to investigate the immunoregulatory mechanism of the interferon system (type I and type III IFNs) against viral infection, the effects of epigenetic modification on virus invasion and escapism host immunity, and the exploration of new viral vaccines and neutralizing nanobodies to combat viral infectious diseases.

英文名

Yanxia Zhu

聯系郵箱

[email protected]

中文簡介

朱艷霞博士主要從事衰老與再生醫學研究，著重于應用干細胞及其衍生物和功能性生物材料逆轉衰老和損傷細胞活性，促進皮膚和骨組織再生。其中一篇關于脂肪干細胞生物學特性的文章他引近1000次。迄今共主持國家自然科學基金3項，參與國家重點研究計劃一項，主持省市級項目多項；發表Nat. Commun.、Adv. Healthc. Mater.等SCI論文30余篇；授權專利5項；獲深圳市科技進步二等獎。

英文簡介

Dr. Yanxia Zhu is primarily engaged in research on anti-aging and regenerative medicine, focusing on the application of stem cells and their derivatives, as well as functional biomaterials to reverse the viability of aging and damaged cells, so as to promote the regeneration of skin and bone tissues. One of her articles on the biological characteristics of adipose-derived stem cells has been cited nearly 1000 times. To date, she has presided over three projects funded by the National Natural Science Foundation of China, participated in a national key research plan, and led multiple provincial and municipal projects. She has published over 30 SCI papers in journals such as Nat. Commun. and Adv. Healthc. Mater., and has been granted five patents. Dr. Zhu has also received the Second Prize for Science and Technology Progress in Shenzhen.

英文名

Wei-Guo Zhu

聯系郵箱

[email protected]

中文簡介

朱教授是深圳大學醫學部講席教授，博士生導師，卡爾森國際腫瘤中心主任，多項科技部“973”及“863”計劃負責人; 國家基金委創新團隊負責人;國家基金委重大及重點項目負責人; 國家杰出青年基金獲得者。

朱教授聚焦探討組蛋白修飾酶和相關的組蛋白修飾在DNA損傷應答、細胞自噬及基因調控等過程中的功能及其在腫瘤發生發展中的作用，發現了一系列重要的腫瘤治療新靶點和新方法，為腫瘤的精準治療提供了重要的理論基礎和實驗支撐。他在國際主流期刊發表180余篇研究論文，包括Nature, Nature Cell Biology, Molecular Cell, PNAS等，被引用15000余次。學術研究主要包括以下三個方面：

1.識別一系列參與腫瘤細胞DNA損傷反應的組蛋白修飾位點/組蛋白修飾酶，為腫瘤放療和化療提供理論依據；

2. 揭示組蛋白修飾酶在自噬多層次調控中的生物學功能；

3.鞏固了蛋白質乙酰化修飾參與腫瘤表觀遺傳治療的理論基礎。

英文簡介

Prof. Zhu is a Chair Professor of Shenzhen University,  and Dean of the International Cancer Center, Shenzhen University, Ph.D Supervisor. He is the head of a number of "973" and "863" programs of the Ministry of Science and Technology of China,  head of the National Funding Commission’s innovation team of NSFC, head of the National Funding Commission’s key R&D program, Recipient of the National Outstanding Distinguished Youth Scientist，as well as the head of major and key projects of the National Foundation Commission of China.

Prof. Zhu focuses on the function of the histone modification enzymes and histone modification in the DNA damage response, autophagy and gene regulation, and its role in cancer development. He found a series of important new targets and methods for cancer treatment, which provides an important theoretical basis and experimental support for the accuracy of tumor therapy. He has published more than 180 research papers in leading international journals including Nature, Nature Cell Biology, Molecular Cell, and PNAS which earned more than 15,000 citations. His academic research mainly includes the following three aspects:

1. Identifying a series of histone modifications sites / histone modifying enzymes that participate in the DNA damage response of tumor cells, providing a theoretical basis for tumor radiotherapy and chemotherapy.

2.  Revealing the biological functions of histone-modifying enzymes in the multi-level regulation of autophagy.

Consolidating the theoretical basis for the involvement of protein acetylation modification in tumor epigenetic therapy.